GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
1. Abbas MG, Shoji H, Soya S, Hondo M, Miyakawa T, Sakurai T. (2015) Comprehensive Behavioral Analysis of Male Ox1r (-/-) Mice Showed Implication of Orexin Receptor-1 in Mood, Anxiety, and Social Behavior. Front Behav Neurosci, 9: 324. [PMID:26696848]
2. Beuckmann CT, Sinton CM, Williams SC, Richardson JA, Hammer RE, Sakurai T, Yanagisawa M. (2004) Expression of a poly-glutamine-ataxin-3 transgene in orexin neurons induces narcolepsy-cataplexy in the rat. J Neurosci, 24 (18): 4469-77. [PMID:15128861]
3. Bonaventure P, Shelton J, Yun S, Nepomuceno D, Sutton S, Aluisio L, Fraser I, Lord B, Shoblock J, Welty N et al.. (2015) Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia. J Pharmacol Exp Ther, 354 (3): 471-82. [PMID:26177655]
4. Chemelli RM, Willie JT, Sinton CM, Elmquist JK, Scammell T, Lee C, Richardson JA, Williams SC, Xiong Y, Kisanuki Y et al.. (1999) Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell, 98 (4): 437-51. [PMID:10481909]
5. Clark JW, Brian ML, Drummond SPA, Hoyer D, Jacobson LH. (2020) Effects of orexin receptor antagonism on human sleep architecture: A systematic review. Sleep Med Rev, 53: 101332. [PMID:32505969]
6. de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS et al.. (1998) The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA, 95 (1): 322-7. [PMID:9419374]
7. Eriksson KS, Sergeeva O, Brown RE, Haas HL. (2001) Orexin/hypocretin excites the histaminergic neurons of the tuberomammillary nucleus. J Neurosci, 21 (23): 9273-9. [PMID:11717361]
8. Evans R, Kimura H, Alexander R, Davies CH, Faessel H, Hartman DS, Ishikawa T, Ratti E, Shimizu K, Suzuki M et al.. (2022) Orexin 2 receptor-selective agonist danavorexton improves narcolepsy phenotype in a mouse model and in human patients. Proc Natl Acad Sci U S A, 119 (35): e2207531119. [PMID:35994639]
9. FDA. FDA approves new type of sleep drug, Belsomra. Accessed on 05/09/2016. Modified on 05/09/2016. FDA.gov, http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm409950.htm
10. Hara J, Beuckmann CT, Nambu T, Willie JT, Chemelli RM, Sinton CM, Sugiyama F, Yagami K, Goto K, Yanagisawa M et al.. (2001) Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity. Neuron, 30 (2): 345-54. [PMID:11394998]
11. Haynes AC, Jackson B, Chapman H, Tadayyon M, Johns A, Porter RA, Arch JR. (2000) A selective orexin-1 receptor antagonist reduces food consumption in male and female rats. Regul Pept, 96 (1-2): 45-51. [PMID:11102651]
12. Ishikawa T, Hara H, Kawano A, Kimura H. (2022) Danavorexton, a selective orexin 2 receptor agonist, provides a symptomatic improvement in a narcolepsy mouse model. Pharmacol Biochem Behav, 220: 173464. [PMID:36108771]
13. Jacobson LH, Hoyer D, de Lecea L. (2022) Hypocretins (orexins): The ultimate translational neuropeptides. J Intern Med, 291 (5): 533-556. [PMID:35043499]
14. Johnson PL, Federici LM, Fitz SD, Renger JJ, Shireman B, Winrow CJ, Bonaventure P, Shekhar A. (2015) OREXIN 1 AND 2 RECEPTOR INVOLVEMENT IN CO2 -INDUCED PANIC-ASSOCIATED BEHAVIOR AND AUTONOMIC RESPONSES. Depress Anxiety, 32 (9): 671-83. [PMID:26332431]
15. Kukkonen JP. (2013) Physiology of the orexinergic/hypocretinergic system: a revisit in 2012. Am J Physiol, Cell Physiol, 304 (1): C2-32. [PMID:23034387]
16. Kukkonen JP. (2017) Orexin/Hypocretin Signaling. Curr Top Behav Neurosci, 33: 17-50. [PMID:27909990]
17. Kukkonen JP, Leonard CS. (2014) Orexin/hypocretin receptor signalling cascades. Br J Pharmacol, 171 (2): 314-31. [PMID:23902572]
18. Leonard CS, Kukkonen JP. (2014) Orexin/hypocretin receptor signalling: a functional perspective. Br J Pharmacol, 171 (2): 294-313. [PMID:23848055]
19. Lin L, Faraco J, Li R, Kadotani H, Rogers W, Lin X, Qiu X, de Jong PJ, Nishino S, Mignot E. (1999) The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene. Cell, 98 (3): 365-76. [PMID:10458611]
20. Marcus JN, Aschkenasi CJ, Lee CE, Chemelli RM, Saper CB, Yanagisawa M, Elmquist JK. (2001) Differential expression of orexin receptors 1 and 2 in the rat brain. J Comp Neurol, 435 (1): 6-25. [PMID:11370008]
21. Nishino S, Ripley B, Overeem S, Lammers GJ, Mignot E. (2000) Hypocretin (orexin) deficiency in human narcolepsy. Lancet, 355 (9197): 39-40. [PMID:10615891]
22. Peyron C, Faraco J, Rogers W, Ripley B, Overeem S, Charnay Y, Nevsimalova S, Aldrich M, Reynolds D, Albin R et al.. (2000) A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med, 6 (9): 991-7. [PMID:10973318]
23. Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S et al.. (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell, 92 (4): 573-85. [PMID:9491897]
24. Scammell TE, Winrow CJ. (2011) Orexin receptors: pharmacology and therapeutic opportunities. Annu Rev Pharmacol Toxicol, 51: 243-66. [PMID:21034217]
25. Steiner MA, Sciarretta C, Pasquali A, Jenck F. (2013) The selective orexin receptor 1 antagonist ACT-335827 in a rat model of diet-induced obesity associated with metabolic syndrome. Front Pharmacol, 4: 165. [PMID:24416020]
26. Trivedi P, Yu H, MacNeil DJ, Van der Ploeg LH, Guan XM. (1998) Distribution of orexin receptor mRNA in the rat brain. FEBS Lett, 438: 71-75. [PMID:9821961]
27. Willie JT, Chemelli RM, Sinton CM, Tokita S, Williams SC, Kisanuki YY, Marcus JN, Lee C, Elmquist JK, Kohlmeier KA et al.. (2003) Distinct narcolepsy syndromes in Orexin receptor-2 and Orexin null mice: molecular genetic dissection of Non-REM and REM sleep regulatory processes. Neuron, 38 (5): 715-30. [PMID:12797957]
28. Wong KK, Ng SY, Lee LT, Ng HK, Chow BK. (2011) Orexins and their receptors from fish to mammals: a comparative approach. Gen Comp Endocrinol, 171 (2): 124-30. [PMID:21216246]
29. Yamamoto H, Nagumo Y, Ishikawa Y, Irukayama-Tomobe Y, Namekawa Y, Nemoto T, Tanaka H, Takahashi G, Tokuda A, Saitoh T et al.. (2022) OX2R-selective orexin agonism is sufficient to ameliorate cataplexy and sleep/wake fragmentation without inducing drug-seeking behavior in mouse model of narcolepsy. PLoS One, 17 (7): e0271901. [PMID:35867683]